A BBC report highlighted that UK Sanfilippo syndrome patients still struggle to access Ultragenyx’s gene therapy Fayuvi (rebisufligene etisparvovec) despite the FDA’s earlier approval in the US. The therapy is priced at about $4 million, and the story describes families raising funds for private treatment abroad while awaiting NHS pathway decisions in the UK. The MPS Society said regulatory assessment processes are required before NHS access can be considered, underscoring that approval in one jurisdiction does not automatically translate to patient availability elsewhere. Ultragenyx has also indicated an expected trajectory for profitability following approval, adding to scrutiny around pricing and access. For biotech stakeholders, the episode spotlights the practical execution gap between regulatory milestones and real-world reimbursement and supply access—particularly for high-cost AAV-based therapies serving small patient populations.
Get the Daily Brief